Rx Analysts (Current / Former) How Did You Think About Exits?

Given that Rx Analysts at the top firms (PJT, HL, EVR, LAZ, MOE) have a plethora of options to choose from, how did you decide between MF/UMM Private Equity (Bx, Apollo, KKR, etc.), Credit (Oaktree, Centerbridge, etc.) Distressed HF's (Aurelius, Angelo Gordon, Silver Point, etc.), L/S Shops (Viking, Maverick, etc.), Special Situations (Apollo HV, Bx TacOps, Ares SpecOps)?

Would love to hear your rationale behind the decision as well and if you would've changed anything.

15 Comments
 

Current Rx analyst, what comes into mind when I think about "exits" relates to 3 topics. Pay, WLB, Work product. In an ideal world it would be best pay, best WLB with most interesting work. It really depends on where YOU want to be in regards to those 3 facets because it differs for every person. A L/S equity , MF buyout and Distressed credit seat are all extremely coveted and will be fruitful. To answer you questions it's about what you want to do. Do you want a family, do you want to try your hand in public markets, do you want to give your life for your job.

That being said, distressed credit seems to be the option I would be most interested in given the high pay, interesting work and better WLB it would bring.

 

How much did your SA work effect how much seniors were willing to go to bat for you during on-cycle/HF recruiting?

Did you have a preference for more public HF or private opportunistic investing for distressed credit roles? 

 
Most Helpful

Currently an analyst at one of the banks mentioned above. I'm going to get a lot of MS for this but in RX you dont really get looks from MF's for their flagship funds ("normal PE"). Not saying there's no chance - but it is very difficult - you'll likely be steered towards their credit/ss arm. If you do RX make sure you really like credit/distressed and are not doing just because its "in" right now - it's a very tough space to be in when things are going really well from a macro perspective and the space is very crowded at the moment. 

 

Eligendi quam repellendus sunt tempora est aut magni qui. Iure rem soluta deserunt similique.

Career Advancement Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

July 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.8%
  • Morgan Stanley 01 98.3%
  • BMO Capital Markets 13 97.7%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.3%
  • Goldman Sachs 01 97.7%
  • JPMorgan 01 97.1%

Total Avg Compensation

July 2026 Investment Banking

  • Vice President (15) $434
  • Associates (46) $258
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (80) $150
  • Intern/Summer Analyst (73) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
kanon's picture
kanon
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
CompBanker's picture
CompBanker
98.9
6
Betsy Massar's picture
Betsy Massar
98.9
7
dosk17's picture
dosk17
98.9
8
DrApeman's picture
DrApeman
98.9
9
GameTheory's picture
GameTheory
98.9
10
Jamoldo's picture
Jamoldo
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”